Active • Host: E. coli • AA: 1-306 of SARS-CoV-2 Mpro Protein (full length), 3,264-3,569 of P0DTD1 • MW: 33.9 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SARS-CoV-2 Mpro Protein

Item No. 30588

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • 3C-like Proteinase
  • Coronavirus Endopeptidase C30
  • Peptidase C30
  • Severe Acute Respiratory Syndrome Coronavirus 2 Mpro
Purity
≥95% estimated by SDS-PAGE
Source
Active recombinant SARS-CoV-2 Mpro expressed in E. coli
Amino Acids
1-306; Location on P0DTD1 3,264-3,569
MW
33.9 kDa
Formulation (Request formulation change)
20 mM HEPES, pH 7.5, with 2.5 mM DTT and 10% glycerol
UniProt Accession №
P0DTD1
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $423

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus and the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.1,2,3,4,5 The SARS-CoV-2 genome contains approximately 30 kilobases and 14 open reading frames (ORFs) that encode four structural proteins: spike, envelope, membrane, and nucleocapsid, as well as 16 non-structural proteins and 9 accessory factors.6 The SARS-CoV-2 main protease (Mpro), also known as 3C-like protease (3CLpro), is encoded within the non-structural protein 5 (nsp5) region of ORF1ab.6 Auto-activation of SARS-CoV-2 Mpro cleaves nsp5-16, which, together with the nsp1-4, form the SARS-CoV-2 replication and transcription complex (RTC), which is critical for the viral replication cycle.6 Inhibition of SARS-CoV-2 Mpro activity reduces SARS-CoV-2 replication in infected cells in vitro, as well as decreases lung viral loads and pulmonary lesions in ACE2 transgenic mice infected with SARS-CoV-2.7,8 Cayman's SARS-CoV-2 Mpro protein can be used for enzyme activity assays.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kandeel, M., Ibrahim, A., Fayez, M., et al. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. J. Med. Virol. 92(6), 660-666 (2020).

    2. Lu, R., Zhao, X., Li, J., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395(10224), 565-574 (2020).

    3. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., et al. Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur. Rev. Med. Pharmacol. Sci. 24(4), 2012-2019 (2020).

    4. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 191, 145-147 (2020).

    5. Yang, F., Shi, S., Zhu, J., et al. Analysis of 92 deceased patients with COVID-19. J. Med. Virol. 92(11), 2511-2515 (2020).

    6. Romano, M., Ruggiero, A., Squeglia, F., et al. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 9(5), 1267 (2020).

    7. Rathnayake, A.D., Zheng, J., Kim, Y., et al. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. Sci. Transl. Med. 12(557), eabc5332 (2020).

    8. Qiao, J., Li, Y.-S., Zeng, R., et al. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model. Science 371(6536), 1374-1378 (2021).